Physician profile
Amit Kumar Rajput
NPI 1457614182
$608.13
in general payments reported to CMS, 2019-2025
12 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.92 · 2021: $138 · 2022: $14.52 · 2023: $93.23 · 2024: $192 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $392 · Education: $36.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.53 |
| Education | $36.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $133.30 | 2019-2021 | |
| Travere Therapeutics, INC. | $123.59 | 2023-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.94 | 2024 | |
| Novartis Pharmaceuticals Corporation | $50.60 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $47.12 | 2023-2024 | |
| Calliditas Therapeutics US INC. | $33.23 | 2023 | Tarpeyo |
| Horizon Therapeutics Plc | $31.06 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.18 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $18.96 | 2024 | |
| Amgen INC. | $17.55 | 2021 | |
| Vifor Pharma, INC. | $15.02 | 2023 | Korsuva, Veltassa |
| Daiichi Sankyo INC. | $14.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Rajput listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.